EMBASSY ACQUISITION/STEVEN DRESNICK SC 13G

Company

Protalix BioTherapeutics, Inc.

Filed

February 24, 1997

Accession Number

0000950144-97-001739

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →